Audit committee requirements
Audit committee requirements in Healthcare & Life Sciences sit at the intersection of securities law, sector-specific compliance obligations, and board governance standards enforced by the U.S. Securities and Exchange Commission, the U.S. Department of Health and Human Services Office of Inspector General, and the European Securities and Markets Authority. The SEC's audit committee independence rules under Exchange Act Rule 10A-3 apply directly to publicly traded life sciences companies, while OIG corporate integrity agreements routinely impose parallel audit committee oversight duties on companies resolving fraud and abuse settlements. Public and private life sciences firms alike are mapping their committee charters against both tracks.
Watch
- OIG corporate integrity agreement audit committee clauses in recent settlements
- SEC Rule 10A-3 independence deficiency notices to life sciences issuers
- ESMA guidance on audit committee financial expertise in pharma-sector listed companies
- Board charter amendments triggered by expanded clinical trial fraud risk disclosures
- HHS OIG work plan items targeting board-level compliance oversight in hospital systems
Recent material activity in Healthcare & Life Sciences
Active monitoring in place across Healthcare & Life Sciences. Material developments related to audit committee requirements will appear here as they are published.